TMO vs V: Which Is the Better Buy?

Side-by-side comparison of Thermo Fisher Scientific Inc. and Visa Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-05-04.
Thermo Fisher Scientific Inc. ยท Healthcare
$462.60
+10.1% upside to fair value
Grade B
VS
Visa Inc. ยท Financial Services
$304.36
+37.7% upside to fair value
High Conviction Grade A-
QuantHub Verdict
V has more upside to fair value (+37.7%). V trades at a lower forward P/E (23.7x). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric TMO V
Current Price $462.60 $304.36
Fair Value Estimate $509.20 $419.00
Upside to Fair Value +10.1% +37.7%
Market Cap $171.9B $586.8B
Forward P/E 25.1x 23.7x
EV / EBITDA 19.0x 22.3x
Price / Sales 3.8x 14.2x
Price / FCF 25.5x 25.6x
Revenue Growth YoY +6.2% +11.3%
Gross Margin 39.4% 81.08%
Operating Margin 17.8% 59.18%
Return on Equity 13.3% 54.22%
Dividend Yield 0% 0.83%
FCF Yield 3.92% 3.91%
Analyst Consensus Strong Buy Strong Buy
Investment Thesis
TMO โ€” Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. operates in the healthcare sector, specializing in medical diagnostics and research tools across four main segments: Laboratory Products and Biopharma Services, Life Sciences Solutions, Analytical Instruments, and Specialty Diagnostics. The company demonstrates medium business quality with steady revenue growth of 6.2% and earnings growth of 9.6% in the most recent qโ€ฆ
V โ€” Visa Inc.
Visa is the world's dominant payment network with $40B in net revenue (FY2025), 50%+ net margins, and a capital-light toll-booth model processing $14.2T in annual payment volume across 257.5B transactions. The business compounds at 10-12% revenue CAGR with operating leverage pushing EPS growth to 12-15% over a cycle, funded by $21.6B in annual free cash flow against only $1.5B in capex. At 28.0x โ€ฆ
Accumulation Zones
Metric TMO V
Zone Low $381.90 $265.00
Zone High $432.82 $300.00
In Buy Zone? No No
โ† TMO Research    V Research โ†’    All Research